This review presents data on dual conjugates of therapeutic and diagnostic action for targeted delivery to prostate cancer cells. The works of the last ten years on this topic were analyzed. The mail attention focuses on low-molecular-weight conjugates directed to the prostate-specific membrane antigen (PSMA); the comparison of high and low molecular weight PSMA-targeted conjugates was made. The considered conjugates were divided in the review into two main classes: diagnostic bimodal conjugates (which are containing two fragments for different types of diagnostics), theranostic conjugates (containing both therapeutic and diagnostic agents); also bimodal high molecular weight therapeutic conjugates containing two therapeutic agents are briefly discussed. The data of in vitro and in vivo studies for PSMA-targeted double conjugates available by the beginning of 2021 have been analyzed.

本综述介绍了靶向递送至前列腺癌细胞的治疗和诊断作用双重偶联物的数据。分析了过去十年有关该主题的作品。邮件关注的重点是针对前列腺特异性膜抗原 (PSMA) 的低分子量偶联物；对高分子量和低分子量 PSMA 靶向偶联物进行了比较。所考虑的偶联物在综述中分为两大类：诊断双峰偶联物（包含用于不同类型诊断的两个片段）、治疗诊断偶联物（同时包含治疗剂和诊断剂）；还简要讨论了包含两种治疗剂的双峰高分子量治疗缀合物。体外和体内数据 对 2021 年初可用的 PSMA 靶向双偶联物的研究进行了分析。